Sensus Healthcare, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Fri, August 14, 2026 at 3:30 PM GMT+3 3 min read

Sensus Healthcare, Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance and Market Dynamics

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Second quarter revenue was significantly impacted by a third-party bank's failure to complete financing approvals for eight units by the quarter-end deadline, despite multiple promises of execution.
Management has terminated the relationship with the failing bank and successfully secured alternative financing for the delayed units, which have already been recognized in the third quarter.
The first half of 2026 focused heavily on market education regarding new CPT codes, helping physicians transition from questioning reimbursement validity to determining how to integrate SRT into their practices.
Commercial momentum is shifting toward larger physician groups and health systems that offer the potential for multi-location adoption and more predictable, diversified growth.
The company is seeing a balanced 50/50 split between direct equipment sales and recurring revenue models, such as the Fair Deal Agreement, which lowers adoption barriers for larger organizations.
International interest is accelerating, particularly in Australia and New Zealand, where skin cancer rates are the highest globally and physician engagement has been strong at recent conferences.

Strategic Outlook and Growth Initiatives

Management expects sequential unit growth to continue through the second half of 2026, targeting 20-plus units per quarter for Q3 and Q4.
The company is prioritizing the conversion of a pipeline built over the last six to nine months, driven by the clarity provided by the new reimbursement environment.
Expansion of recurring revenue remains a top priority, supported by the deployment of inside sales teams to activate Sensus Link software across the existing installed base.
Proposed hospital physician fee schedules suggest a 26% increase for level one radiation., which management believes will further support the economic case for SRT adoption.
Strategic focus remains on driving the company toward sustainable profitability through a mix of high-margin software services and expanded domestic and international system placements.

Financial Adjustments and Risk Factors

The second quarter results included a $5.7 million valuation allowance against net deferred tax assets, contributing to the reported net loss.
Gross margins were pressured by product mix, specifically a higher proportion of international shipments with lower average selling prices and costs related to new Fair Deal Agreement placements.
Management explicitly stated they no longer expect any unit purchases from their formerly largest customer as that organization reevaluates its internal business models.
Inventory levels were maintained at $18.4 million to ensure the ability to support both direct sales and rapid placements as the commercial pipeline converts.

Q&A Highlights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Impact and recovery of the eight delayed financing units

Management clarified that had the financing been approved on time, the company would have reported 19 units for Q2, representing sequential growth from 14 units in Q1.
The eight units were SRT-100 models with an expected average selling price of approximately $250,000 each.

Revenue mix between direct sales and recurring models

Current demand is split roughly 50/50 between outright purchases and recurring revenue models like the Fair Deal Agreement.
Larger physician groups are showing a preference for recurring models, while many individual practices still opt for direct ownership to capture full reimbursement economics.

Growth strategy for Sensus Link software-as-a-service

Sensus Link is being included in almost every new customer agreement, and a dedicated inside sales team is targeting the legacy installed base for activations.
While the monthly fees are smaller than hardware sales, the software carries significantly higher margins and increases daily user engagement with the technology.